Possible myocardial toxicity associated with interleukin-4 therapy

J Immunother Emphasis Tumor Immunol. 1993 Nov;14(4):348-51. doi: 10.1097/00002371-199311000-00015.

Abstract

Interleukin (IL)-4 is a cytokine produced by T lymphocytes, which may play a role in allergic inflammatory processes through its stimulatory effects on immunoglobulin E production and mast cells. In this report, we describe a patient with metastatic melanoma involving the heart who had biopsy-proven myocarditis after treatment with high-dose IL-4. Because of the uncharacteristic predominance of polymorphonuclear and mast cells in the inflammatory infiltrate of this patient's myocardium, we postulate a unique mechanism of IL-4-associated myocarditis. Three other patients treated with IL-4 had less well-defined cardiac abnormalities, suggesting that patients receiving IL-4 may be at risk for cardiac toxicity. Additional studies will be necessary to confirm such an association.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Aged
  • Electrocardiography
  • Female
  • Humans
  • Interleukin-4 / adverse effects*
  • Male
  • Melanoma / therapy
  • Middle Aged
  • Myocarditis / chemically induced*
  • Myocarditis / pathology

Substances

  • Interleukin-4